RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
131 hedge funds and large institutions have $895M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 33 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
131
Holders Change
+12
Holders Change %
+10.08%
% of All Funds
2.92%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
24
Increased
56
Reduced
33
Closed
11
Calls
$3.33M
Puts
$3.86M
Net Calls
-$532K
Net Calls Change
-$5.23M
Top Buyers
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$9.7M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$8.86M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$7.21M |
| 4 |
CI
CPMG Inc
Dallas,
Texas
|
+$6.22M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$5.74M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.2M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$19.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.87M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.87M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.44M |
